Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

Dick Menzies and colleagues report findings from a collaborative, individual patient-level meta-analysis of treatment outcomes among patients with multidrug-resistant tuberculosis.

• Publication year

  2012

• Venue

  PLoS Medicine

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pmed.1001300PMID 22952439PMCID 3429397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis

  2011cited by this paper
• WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

  2011cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.

  2010cited by this paper
• Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

  2010cited by this paper
• Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

  2010cited by this paper
• Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis

  2009cited by this paper
• Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis

  2009cited by this paper
• Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

  2009cited by this paper
• Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

  2008cited by this paper
• Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006.

  2008cited by this paper
• Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study

  2008cited by this paper
• Reviews of Individual Patient Data

  2008cited by this paper
• Extensively drug-resistant tuberculosis in california, 1993-2006.

  2008cited by this paper
• Comprehensive treatment of extensively drug-resistant tuberculosis.

  2008cited by this paper
• Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.

  2008cited by this paper
• Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

  2007cited by this paper
• Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures

  2007cited by this paper
• Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis

  2007cited by this paper
• Clinical and operational value of the extensively drug-resistant tuberculosis definition

  2007cited by this paper
• An intervention programme for the management of multidrug-resistant tuberculosis in France.

  2007cited by this paper
• Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.

  2007cited by this paper
• Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines

  2006cited by this paper
• Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.

  2006cited by this paper
• Public-private collaboration for multidrug-resistant tuberculosis control in New York City.

  2006cited by this paper
• Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study

  2006cited by this paper
• Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment Outcome

  2006cited by this paper
• Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001.

  2006cited by this paper
• Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy.

  2006cited by this paper
• Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control.

  2006cited by this paper
• Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam.

  2006cited by this paper
• Multidrug resistance among persons with tuberculosis in California, 1994-2003.

  2005cited by this paper
• Does DOTS work in populations with drug-resistant tuberculosis?

  2005cited by this paper
• Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach.

  2005cited by this paper
• Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.

  2005cited by this paper
• Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.

  2005cited by this paper
• Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.

  2004cited by this paper
• Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients.

  2004cited by this paper
• Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.

  2004cited by this paper
• Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.

  2004cited by this paper
• Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis.

  2004cited by this paper
• Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

  2004cited by this paper
• Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

  2003cited by this paper
• Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome

  2003cited by this paper
• DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed.

  2003cited by this paper
• Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.

  2003cited by this paper
• Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• ST-14 Handling Missing Data with Multiple Imputation Using PROC MI in SAS

  2002cited by this paper
• Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.

  2002cited by this paper
• Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis.

  2001cited by this paper
• Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997.

  2001cited by this paper
• Multilevel models for meta-analysis, and their application to absolute risk differences

  2001cited by this paper
• Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.

  2000cited by this paper
• Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands.

  2000cited by this paper
• A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

  2000cited by this paper
• Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.

  2000cited by this paper
• Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients.

  2000cited by this paper
• Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model

  1995cited by this paper
• Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis.

  1990cited by this paper
• ON INCURABLE DISTORTIONS OF THE FEET.

  1828cited by this paper

• PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes

  2026cites this paper
• Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

  2025cites this paper
• Using Machine Learning Methods to Predict Early Treatment Outcomes for Multidrug-Resistant or Rifampicin-Resistant Tuberculosis to Enhance Patient Cure Rates: Development and Validation of Multiple Models

  2025cites this paper
• Treatment Outcomes for Drug-Resistant Tuberculosis Patients on Bedaquiline-Based Regimens in a Mostly Rural South Africa

  2025cites this paper
• Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management

  2025cites this paper
• Multidrug-resistant tuberculosis (MDR-TB): an evolving threat to the Nigerian health system – a review

  2025cites this paper
• Current drug susceptibility testing in the Löwenstein-Jensen medium leads to underestimating of prothionamide resistance in multi-drug resistant Mycobacterium tuberculosis

  2025cites this paper
• Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models

  2025cites this paper
• Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings

  2024cites this paper
• Predictors, mortality, and health outcomes of intensive phase non-adherence to a regimen in patients with drug-susceptible tuberculosis: a nationwide linkage database.

  2024cites this paper
• Invasive Procedures Used in Tuberculosis with Questionable Indications: Report from Russia

  2024cites this paper
• Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM

  2024cites this paper
• A publicly accessible global data repository – the WHO TB-IPD platform

  2024cites this paper
• Quantification of MDR-TB drug JBD0131 and its metabolite in plasma via UPLC-MS/MS: application in first-in-human study.

  2024cites this paper
• Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis

  2024cites this paper
• Sputum culture conversion and its predictors among drug-resistant pulmonary tuberculosis patients in eastern Ethiopia

  2024cites this paper
• Machine learning algorithms to predict treatment success for patients with pulmonary tuberculosis

  2024cites this paper
• Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China

  2024cites this paper
• Decoding differentially expressed genes to identify potential immunity associated biomarkers in Tuberculosis: An integrative bioinformatics approach

  2024cites this paper
• Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis

  2024cites this paper
• Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study

  2023cites this paper
• The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates.

  2023cites this paper
• At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States

  2023cites this paper
• Time to Treatment and Risk Factors for Unsuccessful Treatment Outcomes among People Who Started Second-Line Treatment for Rifampicin-Resistant or Multi-Drug-Resistant Tuberculosis in the Kyrgyz Republic, 2021

  2023cites this paper
• Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis

  2023cites this paper
• Coping with drug resistant tuberculosis alongside COVID-19 and other stressors in Zimbabwe: A qualitative study

  2023cites this paper
• Direct Medical Expenses and Influencing Factors of MDR/RR-TB in Eastern China: Based on Data from Multi-Hospital Information Systems

  2023cites this paper
• Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

  2023cites this paper
• Two‐stage targeted maximum likelihood estimation for mixed aggregate and individual participant data analysis with an application to multidrug resistant tuberculosis

  2023cites this paper
• Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment

  2023cites this paper
• Outcomes of bedaquiline containing regimen in the treatment of adults with drug resistant tuberculosis in a tertiary care centre of Rajasthan.

  2023cites this paper
• Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review

  2023cites this paper
• Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

  2023cites this paper
• Coping with drug resistant tuberculosis alongside COVID-19 and other stressors in Zimbabwe: a qualitative study

  2023cites this paper
• The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: A thirteen-year analysis

  2023cites this paper
• Study of Adverse Effects and Outcome of All Oral Longer Regimen for Drug - Resistant Tuberculosis at Nodal DRTB Center, S N M C, Agra

  2023cites this paper
• Advances in computational frameworks in the fight against TB: The way forward

  2023cites this paper
• Evaluation of genetic mutations associated with phenotypic resistance to Fluoroquinolones, Bedaquiline, and Linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.

  2023cites this paper
• Trials underestimate the impact of preventive treatment for household contacts exposed to multidrug-resistant tuberculosis: a simulation study

  2023cites this paper
• Analysis of the Research Hotspot of Drug Treatment of Tuberculosis: A Bibliometric Based on the Top 50 Cited Literatures

  2022cites this paper
• Prevalence and Predictors of Anemia among Drug Resistant Tuberculosis Patients in King Abdulaziz University Hospital, Jeddah

  2022cites this paper
• Single-Fluorescence ATP Sensor Based on Fluorescence Resonance Energy Transfer Reveals Role of Antibiotic-Induced ATP Perturbation in Mycobacterial Killing

  2022cites this paper
• Surgery without Sufficient Indications: an Update from Russia

  2022cites this paper
• Prise en charge thérapeutique des tuberculoses résistantes

  2022cites this paper
• Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country

  2022cites this paper
• Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019

  2022cites this paper
• Chest X-ray Features in Drug-Resistant Tuberculosis Patients in Nigeria; a Retrospective Record Review

  2022cites this paper
• Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis.

  2022cites this paper
• Emerging threat of drug-resistant tuberculosis and trends in the era of COVID-19: A descriptive study from northwestern Nigeria

  2022cites this paper
• Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

  2022cites this paper
• Caregiver willingness to give TPT to children living with drug-resistant TB patients

  2022cites this paper
• Drug resistance patterns, treatment outcomes and factors affecting unfavourable treatment outcomes among extensively drug resistant tuberculosis patients in Pakistan; a multicentre record review

  2022cites this paper
• Characterization of Clofazimine as a Potential Substrate of Drug Transporter

  2022cites this paper
• Treatment options for children with multi-drug resistant tuberculosis

  2022cites this paper
• Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure

  2022cites this paper
• Socioepidemiological status and clinical outcome of MDR TB patients in a tertiary medical college in Southern Odisha

  2022cites this paper
• The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis

  2022cites this paper
• The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art

  2021cites this paper
• The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study

  2021cites this paper
• National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study

  2021cites this paper
• Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis

  2021cites this paper
• QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study

  2021cites this paper
• Some Aspects of the Surgical and Endoscopic Treatment of Tuberculosis in Russia

  2021cites this paper
• Pre treatment and post treatment positron emission tomography-computed tomography (PET-CT) to evaluate treatment response in tuberculous Tubo-Ovarian masses.

  2021cites this paper
• A case series of multidrug‐resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country

  2021cites this paper
• Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]

  2021cites this paper
• Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-western Nigeria

  2021cites this paper
• Sublobectomy is a safe alternative for localized cavitary pulmonary tuberculosis

  2021cites this paper
• Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory

  2021cites this paper
• Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania

  2021cites this paper
• Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR

  2021cites this paper
• WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?

  2021cites this paper
• Does optimized adherence support improve treatment outcomes in RR / MDR-TB patients on 18–20 months regimen in Tbilisi, Georgia?

  2021cites this paper
• A study on treatment outcomes in MDR-TB patients on long term regimen in West Godavari district

  2021cites this paper
• Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting

  2021influential citation
• Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model

  2021cites this paper
• Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis

  2021cites this paper
• Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

  2021cites this paper
• Outcome of drug resistant tuberculosis in Indian children

  2021cites this paper
• Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis

  2021influential citation
• Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis

  2021cites this paper
• Diabetes Mellitus as a Risk Factor for Drug Resistance Tuberculosis: A Retrospective Cohort Study at King Abdul Aziz University, Jeddah

  2021cites this paper
• New ethionamide boosters and EthR2: structural and energetic analysis.

  2021cites this paper
• The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.

  2020cites this paper
• Levofloxacin pharmacokinetics-pharmacodynamics, dosing, and susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis

  2020cites this paper
• WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?

  2020cites this paper
• WHO 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.

  2020cites this paper
• Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice.

  2020cites this paper
• Outcomes of Bedaquiline Treatment in Patients with Multidrug- Resistant –Tuberculosis

  2020cites this paper
• Prevalence of multidrug resistant tuberculosis among TB patients in Malaysia.

  2020cites this paper
• Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance

  2020cites this paper
• Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavorable interim microbiological treatment outcome: An observational study.

  2020cites this paper
• Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.

  2020cites this paper
• Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?

  2020cites this paper
• Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing

  2020cites this paper
• Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa

  2020cites this paper
• Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes

  2020cites this paper
• Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis

  2020cites this paper
• Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen

  2020cites this paper
• A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosis

  2020cites this paper